The role of obesity in the pathogenesis of uterine leiomyoma
https://doi.org/10.31549/2542-1174-2025-9-4-121-132
Abstract
Uterine fibroids are the most common benign monoclonal tumors in gynecological patients. This disease has a high social and economic significance, as it reduces quality of life, work capacity, and reproductive potential in women, and is the most common cause of hysterectomy worldwide. Currently, ongoing research is aimed at identifying new factors influencing the tumorigenesis and growth of fibroid nodules. However, the pathogenesis of uterine fibroids and the full range of causes underlying the variability in tumor growth remain insufficiently understood. In recent years, increasing evidence has highlighted the significant role of adipose tissue and the adipokines it produces in the development of uterine fibroids. The search for such correlations is particularly relevant in the context of the obesity epidemic in developed countries. In this context, we reviewed existing studies available on platforms such as PubMed, Scopus, eLIBRARY, and Cyberleninka, which reflect current understanding of the influence of obesity on the formation and growth of uterine fibroids.
About the Authors
V. K. Babichev
Novosibirsk State Medical University
Russian Federation
Russian Federation
Valentin K. Babichev – Post-Graduate Student, Department of Obstetrics and Gynecology
Novosibirsk
L. A. Piven
Novosibirsk State Medical University
Russian Federation
Russian Federation
Ludlmila A. Piven – Cand. Sci. (Med.), Associate Professor, Department of Obstetrics and Gynecology
Novosibirsk
S. G. Kucherenko
Novosibirsk State Medical University
Russian Federation
Russian Federation
Svetlana G. Kucherenko – Cand. Sci. (Med.), Associate Professor, Department of Obstetrics and Gynecology
Novosibirsk
Т. V. Kiseleva
Novosibirsk State Medical University
Russian Federation
Russian Federation
Тatiana V. Kiseleva – Dr. Sci. (Med.), Professor, Department of Obstetrics and Gynecology
Novosibirsk
Z. B. Khayatova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Zulfiya B. Khayatova – Dr. Sci. (Med.), Professor, Department of Obstetrics and Gynecology
Novosibirsk
I. O. Marinkin
Novosibirsk State Medical University
Russian Federation
Russian Federation
Igor O. Marinkin – Dr. Sci. (Med.), Professor, Head, Department of Obstetrics and Gynecology
Novosibirsk
References
1. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2162-2203. DOI: 10.1016/S0140-6736(24)00933-4.
2. World Health Organization. Obesity and overweight. URL: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed 03.08.2025).
3. More than half of adults worldwide will be over-weight or obese by 2050 – report // The Guardian. 2025, March 3. URL: https://www.theguardian.com/society/2025/mar/03/more-than-half-of-adults-worldwide-obese-by-2050-report-says (accessed 03.08.2025).
4. Reuters, 2025. Obesity rates soaring globally, monumental social failure. URL: https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-rates-soaring-globally-2025-03-03 (accessed 03.08.2025).
5. Alferova V.I., Mustafi na S.V. The prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and Metabolism. 2022;19(1):96-105. DOI: 10.14341/omet12809. (In Russ.)
6. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405(10481):813-838. DOI: 10.1016/S0140-6736(25)00355-1.
7. Li B., Wang F., Chen L., Tong H. Global epidemiological characteristics of uterine fi broids. Arch. Med. Sci. 2023;19(6):1802-1810. DOI: 10.5114/aoms/171786.
8. Soave I., Marci R. From obesity to uterine fi broids: an intricate network. Curr. Med. Res. Opin. 2018;34(11):1877-1879. DOI: 10.1080/03007995.2018.1505606.
9. Malik M., Britten J., Borahay M. et al. Simvastatin, at clinically relevant concentrations, aff ects human uterine leiomyoma growth and extracellular matrix production. Fertil. Steril. 2018;110(7):1398-1407.e1. DOI: 10.1016/j.fertnstert.2018.07.024.
10. Strzałkowska B., Dawidowicz M., Ochman B., Świętochowska E. The role of adipokines in leiomyomas development. Exp. Mol. Pathol. 2021;123:104693. DOI: 10.1016/j.yexmp.2021.104693.
11. Chan J.L., Heist K., DePaoli A.M. et al. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J. Clin. Invest. 2003;111(9):1409-1421. DOI: 10.1172/JCI17490.
12. Broberger C., Johansen J., Johansson C. et al. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc. Natl. Acad. Sci. U. S. A. 1998;95(25):15043-15048. DOI: 10.1073/pnas.95.25.15043
13. Cone R.D. Anatomy and regulation of the central melanocortin system. Nat. Neurosci. 2005;8 (5):571-578. DOI: 10.1038/nn1455.
14. Ray A., Cleary M.P. The potential role of leptin in tumor invasion and metastasis. Cytokine Growth Factor Rev. 2017;38:80-97. DOI: 10.1016/j.cytogfr.2017.11.002.
15. Joo B.S., Park M.J., Kim C.W. et al. Diff erential expression of visfatin, leptin, stromal cell derived factor-1α, endothelial nitric oxide synthase, and vascular endothelial growth factor in human leio-myomas. Gynecol. Endocrinol. 2017;33(4):306-310. DOI: 10.1080/09513590.2016.1255326.
16. Markowska A., Rucinski M., Drews K., Malendowicz L.K. Further studies on leptin and leptin receptor expression in myometrium and uterine myomas. Eur. J. Gynaecol. Oncol. 2005;26(5): 517-525.
17. Ribatti D., Belloni A.S., Nico B. et al. Tryptase- and leptin-positive mast cells correlate with vascular density in uterine leiomyomas. Am. J. Obstet. Gynecol. 2007;196(5):470e1-7. DOI: 10.1016/j.ajog.2006.12.039.
18. Sierra-Honigmann M.R., Nath A.K., Murakami C. et al. Biological action of leptin as an angiogenic factor. Science. 1998;281(5383):1683-1686. DOI: 10.1126/science.281.5383.1683.
19. Ribatti D., Crivellato E., Roccaro A.M et al. Mast cell contribution to angiogenesis related to tumour progression. Clin. Exp. Allergy. 2004;34(11):1660-1664. DOI: 10.1111/j.1365-2222.2004.02104.x.
20. Dingiloglu B.S., Gungor T., Ozdal B. et al. Serum leptin levels in women with uterine leiomyomas. Taiwan J. Obstet. Gynecol. 2007;46(1):33-37. DOI: 10.1016/S1028-4559(08)60103-5.
21. Wolf A.M., Wolf D., Rumpold H. et al. Adiponectin induces the anti-infl ammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 2004;323(2):630-635. DOI: 10.1016/j.bbrc.2004.08.145.
22. Chan K.C., Chou H.H., Wu D.J. et al. Diabetes mellitus has an additional eff ect on coronary artery disease. Jpn. Heart J. 2004;45(6):921-927. DOI: 10.1536/jhj.45.921.
23. Chen H.S., Chan T.F., Chung Y.F. et al. Aberrant serum adiponectin levels in women with uterine leiomyomas. Gynecol. Obstet. Invest. 2004;58(3):160-163. DOI: 10.1159/000079553.
24. Wakabayashi A., Takeda T., Tsuiji K. et al. Antiproliferative eff ect of adiponectin on rat uterine leiomyoma ELT-3 cells. Gynecol. Endocrinol. 2011;27(1):33-38. DOI: 10.3109/09513590.2010.487605.
25. Takeda T., Sakata M., Isobe A. et al. Relationship between metabolic syndrome and uterine leiomyomas: a case-control study. Gynecol. Obstet. Invest. 2008;66(1):14-17. DOI: 10.1159/000114250.
26. Strawn E.Y., Novy M.J., Burry K.A., Bethea C.L. Insulin-like growth factor I promotes leiomyoma cell growth in vitro. Am. J. Obstet. Gynecol. 1995;172(6):1837-1844. DOI: 10.1016/0002-9378(95)91420-X.
27. van der Ven L.T., Gloudemans T., Roholl P.J. et al. Growth advantage of human leiomyoma cells compared to normal smooth-muscle cells due to enhanced sensitivity toward insulin-like growth factor I. Int. J. Cancer. 1994;59(3):427-434. DOI: 10.1002/ijc.2910590323.
28. Sara V.R., Hall K. Insulin-like growth factors and their binding proteins. Physiol. Rev. 1990;70 (3):591-614. DOI: 10.1152/physrev.1990.70.3.591.
29. Suikkari A.M., Koivisto V.A., Koistinen R. et al. Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin. J. Clin. Endocrinol. Metab. 1989;68(1):135-140. DOI: 10.1210/jcem-68-1-135.
30. Suikkari A.M., Koivisto V.A., Rutanen E.M. et al. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J. Clin. Endocrinol. Metab. 1988;66(2):266-272. DOI: 10.1210/jcem-66-2-266.
31. Stefan N., Vozarova B., Funahashi T. et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51(6):1884-1888. DOI: 10.2337/diabetes.51.6.1884.
32. Yamamoto Y., Hirose H., Saito I. et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin. Sci. (Lond.). 2002;103(2):137-142. DOI: 10.1042/cs1030137.
33. Abate N., Haff ner S.M., Garg A. et al. Sex steroid hormones, upper body obesity, and insulin resistance. J. Clin. Endocrinol. Metab. 2002;87(10):4522-4527. DOI: 10.1210/jc.2002-020567.
34. Gkioka E., Msaouel P., Philippou A. et al. Review: The role of insulin-like growth factor-1 signaling pathways in uterine leiomyoma. In Vivo. 2015;29(6):637-649.
35. Shen Q., Zou S., Sheng B. et al. Mifepristone inhibits IGF1 signaling pathway in the treatment of uterine leiomyomas. Drug Des. Devel. Ther. 2019;13:3161-3170. DOI: 10.2147/DDDT.S212157.
36. Fischer R., Maier O. Interrelation of oxidative stress and infl ammation in neurodegenerative disease: role of TNF. Oxidative Med. Cell. Longev. 2015;2015:610813. DOI: 10.1155/2015/610813.
37. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104(4):487-501. DOI: 10.1016/S0092-8674(01)00237-9.
38. Protic O., Toti P., Islam M.S. et al. Possible involvement of infl ammatory/reparative processes in the development of uterine fi broids. Cell Tissue Res. 2016;364(2):415-427. DOI: 10.1007/s00441-015-2324-3.
39. Werner S., Alzheimer C. Roles of activin in tissue repair, fi brosis, and infl ammatory disease. Cytokine Growth Factor Rev. 2006;17(3):157-171. DOI: 10.1016/j.cytogfr.2006.01.001.
40. Islam M.S., Catherino W.H., Protic O. et al. Role of activin-A and myostatin and their signaling pathway in human myometrial and leiomyoma cell function. J. Clin. Endocrinol. Metab. 2014;99(5):E775-E785. DOI: 10.1210/jc.2013-2623.
41. Wolańska M., Taudul E., Bańkowska-Guszczyn E., Kinalski M. Tumor necrosis factor in uterine leiomyomas at various stages of tumor growth. Ginekol. Pol. 2010;81(6): 431-434.
42. Ciebiera M., Włodarczyk M., Wrzosek M. et al. TNF-α serum levels are elevated in women with clinically symptomatic uterine fi broids. Int. J. Immunopathol. Pharmacol. 2018;32: 2058738418779461. DOI: 10.1177/2058738418779461.
43. Sikorski R., Kapeć E., Zaleska W. Serum levels of proinfl ammatory cytokines in women with uterine myomas. Ginekol. Pol. 2001;72(12A):1485-1488.
44. Stolarczyk E. Adipose tissue infl ammation in obesity: a metabolic or immune response? Curr. Opin. Pharmacol. 2017;37:35-40. DOI: 10.1016/j.coph.2017.08.006.
45. Ciebiera M., Wlodarczyk M., Zgliczynska M. et al. The role of tumor necrosis factor alpha in the biology of uterine fibroids and the related symptoms. Int. J. Mol. Sci. 2018;19(12):3869. DOI: 10.3390/ijms19123869.
46. Bao H., Sin T.K., Zhang G. Activin A induces leiomyoma cell proliferation, extracellular matrix (ECM) accumulation and myofi broblastic transformation of myometrial cells via p38 MAPK. Biochem. Biophys. Res. Commun. 2018;504(2):447-453. DOI: 10.1016/j.bbrc.2018.08.171.
47. Solyanikov D.A., Piven’ L.A., Volchek A.V. et al..Correlations between clinical laboratory parameters and angiogenesis and fi brosis markers in myomectomy surgery. Journal of Siberian Medical Sciences. 2023;7(3):109-122. DOI: 10.31549/2542-1174-2023-7-3-109-122.
48. Grodstein F., Goldman M.B., Cramer D.W. Body mass index and ovulatory infertility. Epidemiology. 1994;5(2):247-250. DOI: 10.1097/00001648-199403000-00016.
49. Missmer S.A., Hankinson S.E., Spiegelman D. et al. Incidence of laparoscopically confi rmed endometriosis by demographic, anthropometric, and lifestyle factors. Am. J. Epidemiol. 2004;160(8):784-796. DOI: 10.1093/aje/kwh275.
50. Shah D.K., Correia K.F., Vitonis A.F., Missmer S.A. Body size and endometriosis: results from 20 years of follow-up within the Nurses’ Health Study II prospective cohort. Hum. Reprod. 2013;28(7):1783-1792. DOI: 10.1093/humrep/det120.
51. Qin H., Lin Z., Vásquez E. et al. Association between obesity and the risk of uterine fi broids: a systematic review and meta-analysis. J. Epidemiol. Community Health. 2021;75(2):197-204. DOI: 10.1136/jech-2019-213364.
Review
For citations:
Babichev V.K., Piven L.A., Kucherenko S.G., Kiseleva Т.V., Khayatova Z.B., Marinkin I.O. The role of obesity in the pathogenesis of uterine leiomyoma. Journal of Siberian Medical Sciences. 2025;(4):121-132. https://doi.org/10.31549/2542-1174-2025-9-4-121-132
Views:
7
Email this article 